Evidence map›Paper›PMID 40019045›Full record

ReviewThe Australasian journal of dermatology2025

From Monotherapy to Adjunctive Therapies: Application of Dermocosmetics in Acne Management Across Australia and New Zealand.

Ryan De Cruz, Rebecca Nguyen, Peggy Chen, Delphine Kerob, Kurt Gebauer, Anneliese Willems, Philip Tong, Michael Lee

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Australasian journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ryan De CruzThe Royal Melbourne Hospital, Parkville, Victoria, Australia.
Rebecca NguyenMonash Health, Eastern Health, Clayton, Victoria, Australia.
Peggy ChenPeggy Chen Skin Cancer and Mohs Surgery, New Plymouth, New Zealand.
Delphine KerobLa Roche-Posay Laboratoire Dermatologique, Levallois, France.
Kurt GebauerFremantle Dermatology, Fremantle, Western Australia, Australia.
Anneliese WillemsDepartment of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
Philip TongDigital Dermatology Imaging Program, School of Biomedical Sciences UNSW Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Michael LeeLaye Dermatology, Bondi Junction, New South Wales, Australia.

Funding

L'Oreal
6 · The paper itself

Abstract

Acne vulgaris is a globally prevalent dermatological disease, with its severity ranging from mild to severe. While moderate to severe acne often requires topical or systemic pharmaceutical therapy, mild to moderate acne may be managed with dermocosmetics, which are over-the-counter skincare agents with active ingredients that target acne pathophysiology. Dermocosmetics can also be effective as adjunct therapy for the management of more severe acne. For example, they can be used to complement the mode of action of pharmaceuticals or to mitigate side effects and improve treatment compliance. This review discusses the roles of commonly available dermocosmetics in the context of both mild and severe acne management protocols.

Indexed as

Acne VulgarisDermatologic AgentsAustraliaHumansNew ZealandNonprescription DrugsDermatologic AgentsNonprescription Drugsacne managementacne vulgarisAustraliadermocosmeticsNew Zealand

Identifiers

PMID40019045
PMCPMC12145734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.